

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA373)

NICE GUIDANCE ISSUED DECEMBER 2015

(Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)

Final Appraisal Recommendation

Advice No: 1015 – April 2015

Adalimumab (Humira®)

40 mg solution for injection in pre-filled syringe and pre-filled pen, 40 mg/0.8 ml solution for injection single use vial for paediatric use

Limited submission by AbbVie Ltd

Recommendation of AWMSG

Adalimumab (Humira®) is recommended as an option for use within NHS Wales for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy.

Additional note(s):

- Please refer to the Summary of Product Characteristics for the full licensed indication.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2562), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by the Minister for Health and Social Services and will be considered for review every three years.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at www.evidence.nhs.uk.

For full details on our accreditation visit: www.nice.org.uk/accreditation.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 1015:
adalimumab (Humira[®]) 40 mg solution for injection in pre-filled syringe and pre-filled pen,
40 mg/0.8 ml solution for injection single use vial for paediatric use. April 2015.

